Lutropin alfa
- Generic Name
- Lutropin alfa
- Brand Names
- Luveris, Pergoveris
- Drug Type
- Biotech
- CAS Number
- 152923-57-4
- Unique Ingredient Identifier
- 3JGY52XJNA
- Background
Lutropin alfa is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein made up of monomeric units. Lutropin alfa was the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development. Its pharmacological action mimics the biological activity of endogenous LH; an acute rise of LH, or LH surge, in females triggers ovulation and the development of the corpous luteum. In males, LH stimulates Leydig cell to produce testosterone.
- Indication
For treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound LH deficiency (LH <1.2 international units [IU]/L)
Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression
- Conditions
- Female Infertility Due to Nonimplantation of OvumComplications Associated With Artificial Fertilization
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 5
- Registration Number
- NCT01565265
- Locations
- 🇨🇭
University Hospital of Basel, Basel, Switzerland
A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique
- Conditions
- FertilityInfertilityFollicle Stimulating Hormone Deficiency
- Interventions
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2015-11-09
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 174
- Registration Number
- NCT01497197
- Locations
- 🇦🇪
Merck Serono Research Site, Dubai, United Arab Emirates
A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)
- Conditions
- Infertility
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 600
- Registration Number
- NCT01416987
- Locations
- 🇰🇷
Research site, Seoul, Korea, Republic of
PERgoveriS In Stratified Treatment for Assisted Reproductive Technique
- Conditions
- Assisted Reproductive TechniquesReproductive Technology, Assisted
- Interventions
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 202
- Registration Number
- NCT01297465
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
Lutropin Alfa in Women at Risk of Poor Response
- Conditions
- Ovarian Stimulation
- Interventions
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 58
- Registration Number
- NCT01112358
- Locations
- 🇪🇸
Hospital Universitario de La Fe, Valencia, Spain
To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2009-12-10
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT01029470
- Locations
- 🇨🇳
Peking University third Hospital, Beijing, Beijing, China
The Luveris In Vitro Fertilization Trial
- Conditions
- InfertilityHypothalamic AmenorrheaHyperprolactinemia
- Interventions
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- University Reproductive Associates
- Target Recruit Count
- 14
- Registration Number
- NCT00889512
- Locations
- 🇺🇸
University Reproductive Associates, Hasbrouck Heights, New Jersey, United States
Synchronization of Follicle Wave Emergence and Ovarian Stimulation
- Conditions
- Infertility
- Interventions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- University of Saskatchewan
- Target Recruit Count
- 80
- Registration Number
- NCT00439829
- Locations
- 🇨🇦
Genesis Fertility Centre, Vancouver, British Columbia, Canada
🇨🇦Department of Obstetrics, Gynecology and Reproductive Sciences, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])
- Conditions
- Hypogonadotropic Hypogonadism
- Interventions
- Drug: PlaceboDrug: Recombinant human follicle stimulating hormone (r-hFSH)Drug: Recombinant human chorionic gonadotropin (r-hCG)
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 11
- Registration Number
- NCT00328926
- Locations
- 🇺🇸
U.S. Medical Information, 1-888-275-7376, Rockland, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.